The Food Protection Plan is the comprehensive framework the agency needs to enhance the protection of our nation's food supplyFDA: Food protection plan shows progress Jul 02, 2008
His leadership and service will be critical to FDA's public health mission and regulatory responsibilitiesMasoudi named FDA associate counsel Oct 16, 2007
These labs form the backbone of FDA's work in ensuring the safety of food, medical equipment and cosmeticsSenators ask the FDA to halt lab closings Jan 30, 2007
The future will look no more like the past than a butterfly resembles a caterpillarU.S. starts historic cancer genome project Dec 14, 2005
He understands that basic research is the foundation to any success in eliminating cancer, and that research breakthroughs must be translated into effective treatments for patientsCancer survivor leads national institute Dec 06, 2001
Andrew C. von Eschenbach (born October 30, 1941 in Philadelphia, Pennsylvania) was the Commissioner of the United States Food and Drug Administration from 2006-2009. He became acting Commissioner on September 26, 2005, after the resignation of his predecessor Lester Crawford, and was confirmed as Commissioner by the Senate on December 7, 2006. He was previously the 12th director of the National Cancer Institute.
After graduating from St. Joseph's Preparatory School, Von Eschenbach received his bachelor of science in biology from St. Joseph's University in 1963 and his MD from Georgetown University School of Medicine in 1967. He did residencies at Pennsylvania Hospital in general surgery and urology and taught urology at the University of Pennsylvania School of Medicine. He served in the US Navy Medical Corps with the rank of lieutenant commander from 1968 to 1971.
In 1976, von Eschenbach began his long association with The University of Texas M. D. Anderson Cancer Center, beginning as a urologic oncology fellow and becoming chair of the department of urology in 1983. He was founding director of the Prostate Cancer Research Program in 1996, director of the Genitourinary Cancer Center, and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology. Driven by his father's prostate cancer, he specialized in the disease.